DEPARTMENT OF HUMAN SERVICES
Pharmacy & Therapeutics Committee Minutes
May 17, 2016

Committee Members Present:

Dale Adair, M.D.	OMHSAS Acting Chief Medical Officer
Cheston Berlin, Jr., M.D	Pediatrician
Gene Bishop, M.D.	Internist/Consumer Advocate
Terri Cathers, Pharm.D.,Chair	OMAP Pharmacy Director
Jessica Daw, Pharm.D.	UPMC For You Pharmacist
Andrea Fox, M.D.	Internist
Donald Gerhart, R.Ph.	Community Pharmacist
Heather Gross, Pharm.D.	Aetna Clinical Pharmacist
James Hancovsky, R.Ph., MBA	United Health Care Pharmacy Director
David Haverstick, M.D.	Family Practitioner
David Kelley, M.D.	OMAP Chief Medical Officer
Joshua Liao, M.D.	Internist
Michele Musheno, R.Ph., M.S.	Academic/ Hospital Pharmacist
Ian Paul, M.D.	Pediatrician
James Schuster, M.D., Vice Chair	Psychiatrist
Kevin Szczecina, R.Ph.	Geisinger Health Plan Pharmacist
Andreas Wali, M.D.	Cardiologist
Lloyd Wertz	Consumer/Family Advocate
Eric Yarnell, R.Ph.	Gateway Health Plan Pharmacist
Matthew Zimmerman, Pharm.D.	Health Partners of Philadelphia Pharmacist

Committee Members Not Present:

Ivonne Acrich, M.D.	Ad Hoc Child/Adolescent Psychiatrist
Rosemary Keffer, M.D.	Ad Hoc Adult Psychiatrist
Andrew Maiorini, Pharm.D.	Keystone/AmeriHealth Perform Rx Clinical Pharmacist

Public Testimony Heard by the Committee:

Ed Casey (Pfizer) – Embeda
Devon Shaw (Perdu) – Butrans/Hysingla ER
Ed Casey (Pfizer) – Eliquis
Peter Ishak (Daiichi Sankyo) – Savaysa
Mark Veerman (Jansen) – Xarelto
Contessa Fincher (Teva) – Zecuity
Contessa Fincher (Teva) – Granix
Karen Nguyen (Allergen) – Liletta
Dr. Victoria Meyers (Abington Jefferson Health) – Liletta
Pat Ross (Abington Jefferson Health) – Liletta
Katherine Schott (Planned Parenthood of Western PA) – Liletta
Lin-Fan Fanwang (Missoni Center/Jefferson Health) – Liletta
Jalpa Patel (AstraZeneca) – Movantik
Tosin Tairu (Merck) – Zepatier
Jose Benetiz (Prevention Point Philidelphia) – Removal of disease severity/fibrosis score from Hepatitis C prior authorization guidelines
Kevin Costello (Harvard Law School) –Removal of disease severity/fibrosis score from Hepatitis C prior authorization guidelines
Dr. Michael Dunn (University of Pittsburg) –Removal of disease severity/fibrosis score from Hepatitis C prior authorization guidelines
Suzanna Masartis (Community Liver Alliance) – Removal of disease severity/fibrosis score from Hepatitis C prior authorization guidelines
Dr. Kenneth Rothstein (Drexell University College of Medicine) – Removal of disease severity/fibrosis score from Hepatitis C prior authorization guidelines
Dr Stacey Trooskin (Drexell University College of Medicine) – Removal of disease severity/fibrosis score from Hepatitis C prior authorization guidelines
Bonnie Collins (ViiV) – Triumeq
Ali Toumadj (Gilead) – Odefsey/Descovy
Richard Easom (Novo Nordisk) – Tresiba
Dr. Micahel Raffawle (Sanofi) – Praluent
Contessa Fincher (Teva) – Copaxone 40mg
Dr. Michael Frost (BioDelivery Sciences) - Bunavail
Tom Brock (United Therapeutics) – Orenitram ER
Amber Root (Actelion) - Opsumit

Welcome and Introduction	Dr. Terri Cathers called the meeting to order. Dr. Cathers then welcomed the Committee and the members introduced themselves.
Approval of November 2015 Minutes	The Committee approved the minutes from the November 2015 meeting without revision.
Drug Class Reviews, Public Testimony, Discussion and Voting:	
Acne Agents, Topical	The Committee reviewed the Acne Agents, Topical class. In regard to antibiotic products, the Committee voted in favor of recommending changing clindamycin phosphate (topical) gel, clindamycin phosphate (topical) lotion, clindamycin (topical) solution, erythromycin (topical) solution and Klaron (topical) suspension from preferred to non-preferred status. The Committee unanimously recommended no changes for topical antibiotic combination products. The Committee unanimously recommended adding Benzoyl Peroxide topical cleanser 3% OTC to the PDL as preferred. The Committee also reviewed miscellaneous topical acne medications and unanimously recommended no changes. While reviewing the retinoid products, the Committee unanimously recommended moving Retin-A topical cream 0.025%, 0.05% and 0.1% from non-preferred to preferred. The Committee also unanimously recommended moving tretinoin topical cream 0.025%, 0.05%, 0.1% and tretinoin topical gel 0.01% and 0.025% from preferred to non-preferred status.
Analgesics, Narcotics Long Acting	The Committee reviewed the Analgesics, Narcotics Long Acting class and unanimously recommended adding Belbuca (buccal) film as non-preferred to the PDL as well as moving Kadian (oral) tablet 40mg and 200mg from preferred to non-preferred status.
Analgesics, Narcotics Short Acting	The Committee reviewed the Analgesics, Narcotics Short Acting class and unanimously recommended no changes.
Analgesics, Non-Narcotic Containing Barbiturates	Analgesics, Non-Narcotic Containing Barbiturates was presented as a new PDL class to the Committee. The Committee reviewed the class and unanimously recommended adding all drugs in the class to the PDL as non-preferred. Dr. Cathers stated prior authorization guidelines would be presented to the DUR Board at their September meeting and explained that these PDL recommendations would not go into effect until after the DUR Board meeting.
Androgenic Agents	The Committee reviewed the Androgenic Agents class and unanimously recommended adding Natesto (nasal) gel as non-preferred to the PDL.
Angiotensin Modulators/Angiotensin Modulator Combinations	The Committee reviewed the Angiotensin Modulators class and the Antiotensin Modulator Combinations class and unanimously recommended that captopril-hydrochlorothiazide (oral) tablet be moved to preferred status, Prestalia (oral) tablet and Entresto (oral) tablet will be added as non-preferred to the PDL.
Antibiotics, GI	The Committee reviewed the Antibiotics, GI class and unanimously recommended no changes.
Antibiotics, Inhaled	The Committee reviewed the Antibiotics, Inhaled class and unanimously recommended no changes.
Antibiotics, Topical	The Committee reviewed the Antibiotics, Topical class and unanimously recommended gentamicin sulfate (topical) cream and ointment be moved to preferred status.
Antibiotics, Vaginal	The Committee reviewed the Antibiotics, Vaginal class and unanimously recommended no changes.
Anticoagulants	The Committee reviewed the Anticoagulants class and voted in favor of recommending Eliquis (oral) tablet move from

	non-preferred to preferred status.
Antiemetics/Antivertigo Agents	The Committee reviewed the Antiemetic/Antivertigo Agents class and unanimously recommended adding Varubi (oral) tablet to the PDL as non-preferred.
Antifungals, Oral	The Committee reviewed the Antifungals, Oral class and unanimously recommended Cresemba (oral) capsule added as non-preferred to the PDL.
Antifungals, Topical	The Committee reviewed the Antifungals, Topical class and recommended moving clotrimazole-betamethasone (topical) lotion and Oxistat (topical) lotion to non-preferred.
Antimigraine, Other	The Committee reviewed the Antimigraine Agents, Other class and unanimously recommended no changes.
Antimigraine, Triptans	The Committee reviewed the Antimigraine Agents, Triptans class and unanimously recommended adding almotriptan malate (oral) tablet and Zecuity (transderm) patch IOPH as non-preferred to the PDL.
Antiparasitics, Topical	The Committee reviewed the Antiparasitics, Topical class and unanimously recommended no changes.
Antivirals, Oral	The Committee reviewed the Antivirals, Oral class and unanimously recommended moving rimantadine (oral) tablet to non-preferred.
Antivirals, Topical	The Committee reviewed the Antivirals, Topical class and unanimously recommended no changes.
Beta-Blockers	The Committee reviewed the Beta-Blockers class and unanimously recommended no changes.
Bladder Relaxant Preparations	The Committee reviewed the Bladder Relaxant Preparations class and unanimously recommended no changes.
Bone Resorption Suppression and Related Agents	The Committee reviewed the Bone Resorption Suppression and Related Agents class and unanimously recommended no changes.
Benign Prostatic Hyperplasia (BPH) Treatment	The Committee reviewed the BPH Treatments class and unanimously recommended no changes.
Calcium Channel Blockers	The Committee reviewed the Calcium Channel Blockers class and unanimously recommended moving diltiazem 24HR (oral) capsule 360mg and Tiazac (oral) capsule ER 120mg/180mg/240mg/300mg/360mg to non-preferred.
Cephalosporins and Related Antibiotics	The Committee reviewed the Cephalosporins and Related Antibiotics class and unanimously recommended moving cefaclor (oral) capsule to non-preferred, cefdinir (oral) capsule to preferred, cefprozil (oral) tablet to preferred, cephalexin (oral) capsule 750mg to non-preferred, Suprax (oral) susp recon 100,200mg/5ml and Suprax (oral) suspension 500mg/5ml to non-preferred and amoxicillin-clavulanate (oral) suspension 250-62.5/5 to non-preferred. Post Meeting Note: Following the P&T Committee meeting, DHS clinicans identified that Augmentin 125/31.25 suspension is currently preferred on the PDL and is quite costly in comparison to alternative products. This product may be needed for recipeints less than three months of age, however, in older age groups more cost-effective products could be utilized. In light of this information, the Pharmacy Division recommended non-preferred status for Augmentin 125/31.25 suspension and approval via the prior authorization process when appropriate.

Colony Stimulating Factors	The Committee reviewed the Colony Stimulating Factors class and unanimously recommended adding Zarxio (injection) syringe as non-preferred to the PDL
Contraceptives, Oral	The Committee reviewed the Contraceptives, Oral class and unanimously recommended moving Altavera (oral) tablet, Alyacen (oral) tablet, Apri (oral) tablet, Aviane (oral) tablet, Cyclafem (oral) tablet, Enskyce (oral) tablet, Estarylla (oral) tablet, Generess FE (oral) tab chew, Gildess FE (oral) tablet, Junel FE (oral) tablet, Kurvelo (oral) tablet, Larin FE (oral) tablet, Levora-28 (oral) tablet, Low-ogestrel (oral) tablet, Lutera (oral) tablet, Marlissa (oral) tablet, Mono-linyah (oral) tablet, Mononessa (oral) tablet, Orsythia (oral) tablet, Ortho-cyclen (oral) tablet, Pirmella (oral) tablet, Portia (oral) tablet, Sprintec (oral) tablet, Sronyx (oral) tablet, Wymzya FE (oral) tab chewable, Zenchent FE (oral) tablet chewable, Cyclafem (oral) tablet, Myzilra (oral) tablet, Tri-Estarylla (oral) tablet, Tri-Linyah (oral) tablet, Trinessa (oral) tablet, Loseasonique (oral) tablet 3 month, Deblitane (oral) tablet and Sharobe (oral) tablet to preferred status; adding Blisovi FE (oral) tablet, Cyred (oral) tablet, Juleber (oral) tablet, Kaitlib FE (oral) tab chewable, Vienva (oral) tablet, Tri-Lo-Estarylla (oral) tablet, Tri-Lo-Marzia (oral) tablet, Tri-Lo-Sprintec (oral) tablet and Trinessa Lo (oral) tablet) as preferred; adding Blisovi 24 FE (oral) tablet, Junel FE 24 (oral) tablet, Larin 24 FE (oral) tablet, Layolis FE (oral) tab chewable, Bekyree (oral) tablet, Kimidess (oral) tablet, Ashlyna (oral) tablet 3 month as non-preferred, and moving Femcon FE (oral) tab chew and Microgestin (oral) tablet, levonorgestrel-Eth Estradiol (oral) tablet triphasic and 3 month, Ortho Tri-Cyclen Lo (oral) tablet to non-preferred status.
Contraceptives, Other	The Committee reviewed the Contraceptives, Other class and voted in favor of recommending no changes.
Erythropoiesis Stimulating Proteins	The Committee reviewed the Erythropoiesis Stimulating Proteins class and unanimously recommended no changes.
Fluoroquinolones, Oral	The Committee reviewed the Fluoroquinolones, Oral class and unanimously recommended no changes.
GI Motility, Chronic Agents	The Committee reviewed the GI Motility, Chronic Agents class and unanimously recommended adding alosetron HCL (oral) tablet and Viberzi (oral) tablet as non-preferred to the PDL.
Growth Factors	The Committee reviewed the Growth Factors class and unanimously recommended no changes.
Growth Hormones	The Committee reviewed the Growth Hormones class and unanimously recommended adding Zomacton (Sub-Q) vial as non-preferred.
H. Pylori Treatment	The Committee reviewed the H. Pylori Treatment class and unanimously recommended no changes.
HAE Treatment	The Committee reviewed the HAE Treatment class and unanimously recommended no changes.
Hepatitis B Agents	The Committee reviewed the Hepatitis B Agents class and unanimously recommended no changes.
Hepatitis C Agents	The Committee heard public testimony from several speakers advocating for the removal of disease severity/fibrosis score in the prior authorization guidelines for Hepatitis C Agents. A robust clinical discussion regarding the prior authorization guidelines ensued. The Committee unanimously recommended changing Sovaldi (oral) tablet 400 mg to preferred and adding Zepatier (oral) tablet 50mg-100mg as preferred to the PDL. The Committee unanimously recommended that Ribasphere and ribavirin (oral) tablet be moved to non-preferred. The Committee also voted in favor to remove disease

	severity/fibrosis score from the prior authorization guidelines.
HIV/AIDS	The Committee reviewed the HIV/AIDS class and voted in favor of adding Descovy (oral) tablet 200-25 and Genvoya (oral) tablet 150-200-10 to the PDL as preferred and Odefsey (oral) tablet 200-25-25 as non-preferred. The Committee voted in favor of moving didanosine (oral) capsule DR 125mg/200mg/250mg/400mg and Edurant (oral) tablet 25mg from non-preferred to preferred. The committee voted in favor of moving Complera (oral) tablet 200-25-300, Crixivan (oral) capsule 200mg, Crixivan (oral) capsule 400mg, Intelence (oral) tablet 100mg/200mg/25mg, Invirase (oral) capsule 200mg, Invirase (oral) tablet 500mg, Lexiva (oral) suspension 50mg/ml, Lexiva (oral) tablet 700mg, Stribild (oral) tablet 150-200mg, Triumeq (oral) tablet 600-50-300, Tybost (oral) tablet 150mg, Videx EC (oral) capsule DR 125mg/200mg/250mg/400mg from preferred to non-preferred. Grandfathering applies to this PDL class. The recommendations were also reviewed with Dr. Stacey Trooskin, an infectious disease specialist at Drexell University College of Medicine.
Hypoglycemics, Alpha-Glucosidase Inhibitors	The Committee reviewed the Hypoglycemics, Alpha-Glucosidase Inhibitors class and unanimously recommended no changes.
Hypoglycemics, Incretin Mimetics and Enhancers	The Committee reviewed the Hypoglycemics, Incretin Mimetics and Enhancers class and unanimously recommended Tanzeum (Sub-Q) pen be moved to non-preferred and Victoza (Sub-Q) pen to preferred status.
Hypoglycemics, Insulins	The Committee reviewed the Hypoglycemics, Insulin and Related Agents class and unanimously recommended adding Tresiba Flextouch U-100/200 (Sub-Q) insulin pen as non-preferred to the PDL.
Hypoglycemics, Meglitinides	The Committee reviewed the Hypoglycemics, Meglitinides class and unanimously recommended adding repaglinide-metformin (oral) tablet as non-preferred to the PDL.
Hypoglycemics, Metformins	The Committee reviewed the Hypoglycemics, Metformins class and unanimously recommended metformin HCL ER (oral) tablet 500mg and 1,000mg (generic Glumetza ER) be added as non-preferred to the PDL.
Hypoglycemics, SGLT2 Inhibitors	The Committee reviewed the Hypoglycemics, SGLT2 class and unanimously recommended adding Synjardy (oral) tablet as non-preferred to the PDL.
Hypoglycemics, Sulfonylureas	The Committee reviewed the Hypoglycemics, Sulfonylureas class and unanimously recommended no changes.
Hypoglycemics, TZDs	The Committee reviewed the Hypoglycemics, TZDs class and unanimously recommended no changes.
Immunosuppressives, Oral	The Committee reviewed the Immunosuppressives, Oral class and unanimously recommended adding Envarsus XR (oral) tablet as non-preferred to the PDL; moving Cellcept (oral) suspension and Myfortic (oral) tablet DR to preferred status and moving cyclosporine (oral) capsule and Neoral (oral) capsule to non-preferred status.
Lipotropics, Other	The Committee reviewed the Lipotropics, Other class and unanimously recommended no changes.
Lipotropics, Other	The Committee reviewed the Lipotropics, Other PDL class. Regarding the fibrates, the Committee unanimously recommended adding fenofibrate (oral) tablet 40mg and 120mg as non-preferred to the PDL. The Committee also reviewed the PCSK9 Inhibitors and HoFH Treatments and unanimously recommended moving Kynamro (Sub-Q) syringe 200mg/ml to non-preferred status, adding Praluent (Sub-Q) pen 150/75mg/ml as non-preferred and adding Repatha

	Sureclick (Sub-Q) pen 140mg/ml, and Repatha (Sub-Q) syringe/pen 140mg/mlas preferred to the PDL.
Lipotropics, Statins	The Committee reviewed the Lipotropics, Statins class and unanimously recommended adding fluvastatin ER (oral) tablet ER 24HR as non preferred to the PDL.
Macrolides/Ketolides	The Committee reviewed the Macrolides/Ketolides class and unanimously recommended moving clarithromycin (oral) suspension and tablet, E.E.S 200 (oral) suspension 200mg/5ml, Eryped 400 (oral) suspension 400mg/5ml, ERY-TAB (oral) tablet DR 250mg/333mg/500mg to non-preferred.
Multiple Sclerosis Agents	The Committee reviewed the Multiple Sclerosis Agents class and unanimously recommended adding Glatopa (Sub-Q) syringe 20mg/ml as non-preferred to the PDL.
Nitrofuran Derivatives	The Committee reviewed the Nitrofuran Derivatives class and unanimously recommended Macrobid (oral) capsule and Macrodantin (oral) capsule be moved to non-preferred status.
Opiate Dependence Treatments	The Committee reviewed the Opiate Dependence Treatments class and unanimously recommended no changes
Opiate Overdose Agents	Opiate Overdose Agents was presented as a new class to the PDL. Several of these products had previously been included in the Opiate Dependence Treatments class. This modification promotes review of similar products within the two PDL classes. The Committee reviewed the medications and unanimously recommended adding Narcan (nasal) spray as preferred to the PDL.
Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled	The Committee reviewed the PAH Agents, Oral and Inhaled class and unanimously recommended adding Uptravi (oral) tablet as non-preferred to the PDLand moving Tracleer (oral) tablet to non-preferred status.
Pancreatic Enzymes	The Committee reviewed the Pancreatic Enzymes class and unanimously recommended no changes.
Phosphate Binders	The Committee reviewed the Phosphate Binders class and unanimously recommended moving Renvela (oral) tablet to preferred status, calcium acetate (oral) capsule to non-preferred status and adding Fosrenol (oral) powder as non-preferred to the PDL.
Pituitary Suppressive Agents, LHRH	The Committee reviewed the Pituitary Suppressive Agents, LHRH class and unanimously recommended no changes.
Platelet Aggregation Inhibitors	The Committee reviewed the Platelet Aggregation Inhibitors class and unanimously recommended no changes.
Prenatal Vitamins	The Committee reviewed the Prenatal Vitamins class and unanimously recommended moving, Completenate (oral) tablet chewable, Folivane-OB (oral) capsule, PNV 29-1 (oral) tablet, , Taron-C DHA (oral) capsule, Triveen-Duo DHA (oral) combination package, Ultimatetcare One (oral) capsule, , Virtprex (oral) capsule, Virt-Select (oral) capsule, Vol-Nate (oral) tablet, Zatean-PN DHA (oral) capsule and Zatean-PN Plus (oral) capsule to non-preferred status.
Proton Pump Inhibitors	The Committee reviewed the Proton Pump Inhibitors class and unanimously recommended adding esomeprazole magnesium (oral) capsule as non-preferred to the PDL.
Skeletal Muscle Relaxants	The Committee reviewed the Skeletal Muscle Relaxants class and unanimously recommended no changes.

Tetracyclines	The Committee reviewed the Tetracyclines class and unanimously recommended moving tetracycline HCL (oral) capsule to non-preferred status and moving Vibramycin (oral) suspension to preferred status.
Thyroid Hormones	The Committee reviewed the Thyroid Hormones class and unanimously recommended moving Levoxyl (oral) tablet to non-preferred status.
Ulcerative Colitis Agents	The Committee reviewed the Ulcerative Colitis Agents class and unanimously recommended moving Delzicol (oral) capsule to preferred status and Pentasa (oral) capsule to non-preferred status.
Vasodilators, Coronary	The Committee reviewed the Vasodilators, Coronary class and unanimously recommended moving isosorbide dinitrate 10mg/20mg/30mg/5mg tablets, Minitran 0.1mg/0.2mg/0.4mg/0.6mg/hr patch to non-preferred status and moving isosorbide dinitrate (sublingual) tablet 2.5mg to preferred status.
Meeting Adjourned	Dr. Cathers thanked the Committee for their participation and adjourned the meeting.